Randomized Clinical Trial To assess the effecacy of Aragwadhadi taila in comparison with betadine liquid in management of Dushta vrana
Phase 2
- Conditions
- Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified
- Registration Number
- CTRI/2022/07/044160
- Lead Sponsor
- DR AMRUTA ARVIND NARKAR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients having sign and symptoms of Dushta Vrana i.e.infected wound.
2.Dushta Vrana size up to 5Ã?5cms (LxB)
3.Patients of either sex will be selected.
4.The patients of age group 19 - 70 years
Exclusion Criteria
1.Anaemic patient Hb < 10 gm
2.Malnourished patient (as per age, height and weight proportion)
3.Bleeding disorders (increased B.T and C.T)
4.Patient with septicemia
5.The patients suffering from systemic disease such as AIDS, Tuberculosis, Uncontrolled Diabetes mellitus, Hepatitis-B, Malignancy, Vericose ulcer, Deep vein thrombosis, Neurogenic ulcer, Leukemia, etc.
6.Any congenital diseases or abnormalities.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)Dushta vrana (infected wound) has been explained as a stage of vrana in many classical texts. Also, Dushta vrana (infected wound) has been mentioned as a type of vrana (wound). <br/ ><br>2)To evaluate the eshtablish safer, cost-effective aragwadhadi taila in the management of dushta vrana (infected wound)Timepoint: 15 Days of study (0,5,10,15 days)
- Secondary Outcome Measures
Name Time Method Aragwadhadi Taila is effective management of dushta vranaTimepoint: 15 days of study (0,5,10,15)